Hodgkin lymphoma, also known as Hodgkin's lymphoma or Hodgkin's disease, is a type of lymphoma, in which cancer originates from white blood cells called lymphocytes.
Biotherapy options have emerged for patients with B-lineage Non-Hodgkins Lymphoma (NHL). A series of novel mAbs with specificity for a variety of surface antigens are currently under evaluation. Rituximab used both for biotherapy of patients with B-lineage NHL who experience a recurrence of their disease after frontline therapy as well as for frontline treatment of B-lineage NHL patients who are at high risk to experience a recurrence after chemotherapy. Hodgkin Lymphoma (HL) shows a 3rd month anti-TNF therapy which needs to be modified and pursue immunosuppressive therapy with anti-TNF drugs, which were also used in the treatment of rheumatic diseases.
High-impact journals are those considered to be highly influential in their respective fields. The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
Last date updated on January, 2021